By CHAD BRAY
Hikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States.
Published: July 29, 2015 at 12:00AM
Read more at: NYT Business Day
Subscribe
Login
0 Comments
Newest
- Related Content by Tag
- NYT